DC Circuit: US ex rel. Kennedy v. Novo Nordisk
The brief addresses the proper interpretation of the alternate remedy provision of the FCA, argues that relators should not be precluded from receiving a share of an alternate remedy when the government intervenes, and explains the negative impact such a rule would have on the qui tam provisions of the FCA.